Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The Serena 6 trial's PFS2 data is difficult to interpret because only 13% of the control arm received a next-generation oral SERD post-progression. This low crossover rate makes it hard to definitively conclude if switching to camazestrant early is superior to switching later, as the control group's subsequent treatment was not the modern standard of care.
Related Insights
The debate over the SERENA-6 trial centers not on drug efficacy, but on its unique design. Intervening at molecular relapse (ESR1 mutation) instead of clinical progression creates a new patient population that doesn't fit neatly into first-line maintenance or second-line treatment categories. This ambiguity complicates regulatory interpretation and defining the appropriate control arm.
The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.
The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.
In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.
Despite showing a progression-free survival (PFS) benefit, oncologists advise against the SERENA-6 strategy of switching therapy upon detecting an ESR1 mutation before clinical progression. The lack of overall survival data, flawed trial comparison (PFS vs PFS2), and significant cost burdens make this approach premature for clinical practice.
The control arm in the EMBARK study was blinded to PSA results, preventing physicians from intervening with standard-of-care AR antagonists at PSA progression. This design likely delayed subsequent effective therapies, making the control arm underperform and potentially exaggerating the overall survival benefit of the experimental arms.
The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.
While the Lidera trial showed a benefit for the oral SERD giredestrant in the adjuvant setting, experts advise caution before changing practice. The trial's control arm (standard endocrine therapy) does not reflect the current standard of care for high-risk patients, which now includes CDK4/6 inhibitors, making a direct comparison difficult.
The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.
Experts are divided on switching to an oral SERD based on detecting an ESR1 mutation before radiologic progression. A key counterargument is that this is not the patient's only chance to receive the drug, and the strategy may offer less progression-free survival than waiting for clinical progression.
